Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Essentials for Clinicians: Neuro-Oncology - Editors and Contributors

Editors

  • Matthias Preusser, Department of Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria
  • Michael Weller, Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland

Series editor: Michele Ghielmini, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Contributors

Chapter 1 - Epidemiology, Pathogenesis and Risk Factors of Brain Tumours

  • L Bauchet - Department of Neurosurgery and French Brain Tumor DataBase, Hôpital Gui de Chauliac, Montpellier, France
  • V Rigau - Department of Pathology and French Brain Tumor DataBase, Hôpital Gui de Chauliac, Montpellier, France

Chapter 2 - Clinical Presentation, Differential Diagnosis and Response Assessment of Gliomas

  • R Henriksson - Regional Cancer Centre Stockholm Gotland; Department of Radiation Sciences, Umeå University Hospital, Umeå, Sweden
  • M Bergqvist - Department of Oncology, Gävle Hospital, Gävle, Sweden; Department of Radiation Sciences & Oncology, Umeå University Hospital, Umeå, Sweden

Chapter 3 - Histology and Molecular Pathology of Gliomas

  • P Wesseling - Department of Pathology, VU University Medical Center/Brain Tumor Center, Amsterdam, Netherlands; Diagnostic Laboratory, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pathology, University Medical Center Utrecht, Netherlands

Chapter 4 - Treatment Strategies for Anaplastic Astrocytoma and Glioblastoma

  • M Weller - Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
  • M Hegi - Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery, Department of Clinical Neurosciences, University Hospital Lausanne, Lausanne, Switzerland

Chapter 5 - Treatment Strategies for Low-grade Gliomas

  • BG Baumert - Department of Radiation-Oncology, MediClin Robert-Janker-Clinic; Clinical Cooperation Unit Neurooncology, University of Bonn Medical Centre, Bonn, Germany and Department of Radiation-Oncology, Paracelsus Clinic Osnabrueck, Germany
  • AF Hottinger - Departments of Clinical Neurosciences & Oncology, CHUV Lausanne University Hospital, Lausanne University, Lausanne, Switzerland

Chapter 6 - The Essentials in Radiation Oncology for Brain Tumours

  • M Brada - Academic Unit of Radiation, Oncology Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
  • T Ajithkumar - Department of Clinical Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Chapter 7 - Surgery, Indications and Limitations

  • O Schnell - Department of Neurosurgery, Klinikum der Ludwig-Maximilians-Universität München Campus Grosshadern, Munich, Germany; Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany
  • J-C Tonn - Department of Neurosurgery, Klinikum der Ludwig-Maximilians-Universität München Campus Grosshadern, Munich, Germany

Chapter 8 - Management of CNS Metastases

  • M Preusser - Department of Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria

 Chapter 9 - Treatment of Oligodendroglioma (IDHmt, 1p/19q Codeleted)

  • F Ducray - Neuro-Oncology, Hôpital Neurologique de Lyon, Lyon, France
  • MJ van den Bent - Department of Neuro-Oncology/Neurology, Erasmus MC Cancer Center, Rotterdam, Netherlands

Chapter 10 - Classification and Treatment Strategies of Meningiomas

  • C Mawrin - Department of Neuropathology, Otto-von-Guericke-University, Magdeburg, Germany
  • M Preusser - Department of Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria

Chapter 11 - Classification and Treatment of Paediatric Brain Tumours

  • R Riccardi - Università Cattolica del Sacro Cuore, Rome, Italy
  • D Rizzo - Università Cattolica del Sacro Cuore, Rome, Italy
  • F Giangaspero - Department of Radiological, Oncological and Anatomopathological Sciences, University Sapienza of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy

Chapter 12 - Anticoagulation and Management of Seizures and Brain Oedema in Brain Tumour Patients

  • C Marosi - Medical University of Vienna, Clinical Division of Medical Oncology, Department for Internal Medicine I, Vienna, Austria
  • S Oberndorfer - Department for Neurology, University Clinic St. Pölten, KLPU, KLI-Clinical Neurology and Neuropsychology, St. Pölten, Austria

Chapter 13 - Management of Spinal Tumours

  • S-O Eicker - Department of Neurosurgery, University Medical Center, Hamburg-Eppendorf, Germany
  • M Westphal - Department of Neurosurgery, University Medical Center, Hamburg-Eppendorf, Germany

Declarations of interest

  • T Ajithkumar: No conflicts of interest.
  • L Bauchet: No conflicts of interest.
  • BG Baumert: Travel support from MSD, Roche, Noxxon; compensation for advisory board participation from Noxxon.
  • M Bergqvist: Advisory board for Lilly Pharma, MSD, Bristol-Myers-Squibb.
  • M Brada: No conflicts of interest.
  • F Ducray: Research support from Roche, GlaxoSmithKline, Bristol-Myers-Squibb, UCB, Novocure.
  • S-O Eicker: Scientific advisor for Stryker, Spineart.
  • F Giangaspero: No conflicts of interest.
  • M Hegi: Compensation for lectures or advisory board participation from MSD, Roche/Genentech, MDxHealth, Novocure.
  • R Henriksson: No conflicts of interest.
  • AF Hottinger: Travel support from Roche, MSD, Novocure.
  • C Marosi: No conflicts of interest.
  • C Mawrin: No conflicts of interest.
  • S Oberndorfer: No conflicts of interest.
  • M Preusser:Research support from Böhringer- Ingelheim, GlaxoSmithKline, Merck Sharp & Dome, Roche; honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca.
  • R Riccardi: No conflicts of interest.
  • V Rigau: No conflicts of interest.
  • D Rizzo: No conflicts of interest.
  • O Schnell: Honoraria for advisory board participation or consulting from Novocure, Roche.
  • J-C Tonn: No conflicts of interest.
  • MJ van den Bent: Research support from Roche, Abbvie; honoraria from Roche, Abbvie, Novocure, Actelion, Merck Ag, Cavion.
  • M Weller: Research grants from Acceleron, Actelion, Alpinia Institute, Bayer, Isarna, MSD, Merck & Co, Novocure, PIQUR, Roche; honoraria for lectures or advisory board participation or consulting from Celldex, Immunocellular Therapeutics, Isarna, Magforce, MSD, Merck & Co, Northwest Biotherapeutics, Novocure, Pfizer, Roche, Teva.
  • P Wesseling: No conflicts of interest.
  • M Westphal: No conflicts of interest.
1- Epidemiology, Pathogenesis, Risk Factors of Brain Tumours

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings